drugset / Trial / NCT00003792
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Treatment
Summary
RATIONALE: Vaccines made from a person's white blood cells and melanoma cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma.
Timeline
- Start
- 1999-04
- Primary completion
- —
- Completion
- 2006-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MART-1 antigen | Vaccine | — | Subcutaneous |
| Subject | MELANOMA-ASSOCIATED ANTIGEN 3 | Protein / enzyme biologic | — | Subcutaneous |
| Subject | flu matrix peptide p58-66 | Peptide | — | Subcutaneous |
| Subject | gp100 antigen | Peptide | — | Subcutaneous |
| Subject | tyrosinase | Peptide | — | Subcutaneous |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |